Could a liver transplant from a living donor help fight colorectal cancer that spread?
NCT ID NCT05248581
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study creates a registry to track outcomes of living donor liver transplants in adults with colorectal cancer that has spread to the liver and cannot be removed by surgery. Researchers will collect medical data to see how long patients live without the cancer returning and overall survival at 1, 3, and 5 years. The goal is to understand if this procedure can be a viable treatment option for this group of patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- living donor liver transplantation
- What this could lead to
- If successful, this approach could offer a new treatment option for patients with colorectal cancer that has spread to the liver and cannot be removed by standard surgery.
- What could go wrong
- This is a small registry study, not a controlled trial, so it cannot prove the procedure works. Liver transplant carries major risks, including rejection and lifelong anti-rejection medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 25 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2019
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Potential subjects for this registry must have Stage IV colorectal cancer with liver metastases and be candidates for liver transplantation based on multidisciplinary discussion by a tumor board.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 * Non-amenable to curative hepatic resection as defined by FLR \<30% * Histologically confirmed adenocarcinoma of the colon or rectum * Candidate for LDLT for colorectal liver metastasis per the University of Rochester liver transplant program Exclusion Criteria: * Not a candidate of the LDLT liver transplant protocol for treatment of colorectal liver metastasis. * Unwilling to consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer metastatic are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a vaccine boost immunotherapy against a stubborn cancer?
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Chemo holidays put to the test: can scheduled breaks beat continuous treatment for advanced colorectal cancer?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Experimental drug SHR-A1904 takes on Hard-to-Treat colorectal cancer